3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDIV
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Lung Neoplasms
18
Carcinoma, Non-Small-Cell Lung
18
Breast Neoplasms
6
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Colorectal Neoplasms
5
Mesothelioma, Malignant
4
Colonic Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Carcinoma, Renal Cell
3
Adenocarcinoma of Lung
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma
2
Melanoma
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Interventions
Carboplatin
12
Pemetrexed
11
pembrolizumab
10
Paclitaxel
6
Cisplatin
6
Erlotinib Hydrochloride
5
Docetaxel
5
Nivolumab
4
Gefitinib
4
spartalizumab
3
osimertinib
3
Gemcitabine
3
EC145
3
Crizotinib
3
Afatinib
3
technetium 99m etarfolatide
2
pralsetinib
2
fludarabine
2
cemiplimab
2
brigatinib
2
alpha-2'-deoxythioguanosine
2
aldesleukin
2
Vinorelbine
2
Radiotherapy
2
Quality of Life
2
MORAb-202
2
Immunotherapy
2
Drug Therapy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
sargramostim
×
Thoracic
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled